Impact of EML4-ALK Variant on Resistance Mechanisms and Outcomes in ALK-Positive Lung Cancer.

Advanced anaplastic lymphoma kinase (ALK) fusion-positive non–small-cell lung cancers (NSCLCs) are effectively treated with ALK tyrosine kinase inhibitors (TKIs). However, clinical outcomes in these patients vary, and the benefit of TKIs is limited as a result of acquired resistance. Emerging data suggest that the ALK fusion variant may affect clinical outcome, but the molecular basis …

Impact of EML4-ALK Variant on Resistance Mechanisms and Outcomes in ALK-Positive Lung Cancer. Read More »